Clinical utility of PSMA PET/CT for recurrent prostate cancer

Phase 2

• Conditions: prostate cancer; prostate cancer, PSMA, PET

• Registration Number: JPRN-jRCTs051180037
• Lead Sponsor: akamoto Yuji

Brief Summary

PET/CT using 18F-FSU-880 would be useful in patients with suspected recurrence after primary treatment of prostate cancer.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-29
• Study Completion: 2021-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 74

Inclusion Criteria

1. Patients (Age 20-85 y.o.) with prostate cancer
2. Patients who are suspected of having recurrence due to their increased PSA or diagnostic imaging after surgery for prostate cancer
3. Patients who are determined to be appropriate for this study by participating physicians according to the results of physical examination and blood/urine/physiological function tests.
4. Patients who give us written informed consent

Exclusion Criteria

1. Patients having a severe communication problem.
2. Patients with severe general condition.
3. Patients having severe renal dysfunction (eGFR<30 mL/min/1.73m3) expected to affect the distribution of [18F]FSU-880..
4. Patients to whom participating physicians judged to be inappropriate for this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified